| Name of the Formulation | Licensed Annual capacity - (COB Licence 1971) | Highest Prodn. during the 1st 5 years |
|---|---|---|
| 3. *Tablets* : | | |
| (a) Bevidox<br>(b) Cecon '500'<br>(c) Erythrocin 100 mg.<br>(d) Erythrocin 250 gm.<br>(e) Iberol<br>(f) Optilets<br>(g) Optilets M<br>(h) Primilets<br>(i) Sucaryl<br>(j) Surbex Sugar Coated<br>(k) Surbex T | 100 (one hundred million) tablets | 141.2 millions. |
| 4. *Capsules* : | | |
| (a) Nembutal<br>(b) Tridione | 800.000 (Eight lakh) Numbers | 242.8 '000 Nos. |
| 5. *Granules* : | | |
| (a) Erythoricin<br>(b) Pentothal Sodium | 5,737 (Five thousand seven hundred thirty seven) Kgs. | 20902.6 kgs. |

(h) and (i) The re-endorsement is subject to the condition that the company shall reach the ratio of 1:10 between the value of production of bulk drugs and formulations within a period of 2 years from the date of re-endorsement of capacities failing which the company shall have to export their entire formulations or such portion of the formulation which is beyond the ratio of 1:10.

**Vacancies of High Court Judges in J & K**

2306. SHRI GHULAM RASOOL KAR: Will the Minister of LAW AND JUSTICE be pleased to state:

(a) whether Government of the State of Jammu and Kashmir have recently recommended for the creation of another two posts of Judges in the High Court for Jammu and Kashmir State;

(b) whether it is a fact that there already exists one vacancy of a judge in that High Court; and

(c) whether the recommendations of the State Government are likely to be accepted and vacancies filled up at the earliest?

THE MINISTER OF STATE IN THE MINISTRY OF LAW AND JUSTICE (SHRI H. R. BHARDWAJ): (a) No such proposal has been received.

(b) Yes, Sir.

(c) The matter of filling up the existing vacancy is engaging the attention of the Government in consultation with the State Government.

**Non-utilisation of capacity for the production of drug by I.D.P.L.**

2307. SHRI BHAGATRAM MANHAR: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 559 in the Rajya Sabha on the 6th May, 1985 and state:

(a) what are the reasons for non-utliisation of capacity available with IDPL for the manufacture of Glybenclamide;

(b) whether IDPL is marketing any formulation based on this drug; if so, the name of the formulation, the price fixed for each pack and strength;

(c) what was the bulk drug price taken into account for working out the formulation price;

(d) whether IDPL sold any quantity to non-associated formulators; and

(e) if so, what are the details thereof indicating the name of the party, the quantity and the price charged?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) IDPL have not installed any capacity for the commercial manufacture of Glybanclamide. However, in course of Research and Development work in-house, certain quantity was produced and used.

(b) and (c) IDPL marketed the formulation under brand name of 'Idimide' based on Glybenclamide. The strength is 5 mg/tablet. IDPL follows the leader price of Rs. 6.65 (including excise duty) fixed for a pack of 10x10 tablets.

(d) and (e) As the IDPL did not undertake commercial production of Glybenclamide bulk, the question of sale of the same to any non-associated formulator does not arise.

**Association of Multinationals or Non-resident Indains with construction of fertilizer plants**

2308. SHRI K. VASUDEVA PANICKER: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state.

(a) whether any multinational firm or non-resident Indians are associated with the setting up of new fertilizer units under erection; and

(b) if so, what are the details thereof?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) and (b) M/s. Caparo Group, London, has offered to set up a gas-based fertilizer project at Shahjahanpur in U.P., at an estimated cost of Rs. 620 crores, with 50 per cent of the equity as non-resident Indian investment.

**Manufacture of drugs of doubtful validity**

2309. SHRI RAJNI RANJAN SAHU: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 2826 given in the Rajya Sabha on the 22nd August, 1983 and state:

(a) whether it is a fact that the manufacturers are increasing production of formulations of doubtful validity which are exempted from price control;

(b) whether it is a fact that Government neither allowed re-endorsement nor instructed the companies to stop production;

(c) what was the production of each product for the previous three years, year-wise, as mentioned in the application for re-endorsement of capacity by each company and what was their production during 1984-85;

(d) what are the names of the formulations of each company of doubtful validity, based on imported and canalised bulk drugs;

(e) what was the consumption of each drug by each company during 1979-80 and 1984-85;

(f) what are the reasons for not putting restriction on their imports and allocations of canalised drugs;

(g) whether it is also a fact that companies are marketing without price approval and overcharging and expanding production unauthorisedly; and

(h) if so, what action was taken against them?